Taro Mizuno

Dr. Taro Mizuno

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
YNYukiya Narita
Yukiya Narita
TMTaro Mizuno
Taro Mizuno
TSTakato Suda
Takato Suda
JKJunko Kurono
Junko Kurono
YIYasunobu Ishizuka
Yasunobu Ishizuka
KMKei Muro
Kei Muro
Background: Zolbetuximab, a monoclonal antibody targeting claudin-18.2 (CLDN18.2), which was recently approved as first-line treatment for advanced gastric cancer (AGC), presents unique safety challenges, particularly infusion-related gastrointestinal toxicity and hypoalbuminemia. This study aimed to present our experience with zolbetuximab administration in patients with AGC, focusing on the safety and management effectiveness of our adapted protocol in routine clinical practice. Methods: This study presents our single-institution real-world experience implementing a proactive management protocol (“Project VYLOY”) using zolbetuximab to mitigate these toxicities. We adopted a standardized stepwise infusion protocol and antiemetic premedication to reduce infusion-related nausea and vomiting. Patients with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who received zolbetuximab combined with chemotherapy were included. Results: Twenty-four patients were included. The median infusion duration was 215 min, with an interruption rate of 25.0%. In cycle 1, 62.5% experienced infusion-associated adverse events, primarily grade 1 nausea (54%) and vomiting (25%). Hypoalbuminemia (grade ≥ 2) occurred in 57% of first-line patients, potentially linked to zolbetuximab-induced gastritis and gastrointestinal protein loss. Proactive antiemetic support and infusion rate adjustments substantially reduced infusion interruptions in subsequent cycles (10.9%). Patients without prior gastrectomy had higher nausea and vomiting rates, confirming the stomach’s role in mediating toxicity. Conclusions: Our results suggest that proactive management can improve the safety and tolerability of zolbetuximab, especially by reducing infusion-related toxicity in real-world practice.

2 December 2024 in The Oncologist
Verified
Journal Article
Open access
YNYukiya Narita
Yukiya Narita
TMTaro Mizuno
Taro Mizuno
YIYasunobu Ishizuka
Yasunobu Ishizuka
TSTomoki Sakakida
Tomoki Sakakida
TMToshiki Masuishi
Toshiki Masuishi
KMKei Muro
Kei Muro
Purpose: Human epidermal growth factor receptor 2 (HER2) status is a critical biomarker in advanced gastric cancer (AGC). While the role of HER2-positive tumors in guiding targeted therapies is well-established, the clinical implications of HER2-low expression, defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative (ISH-negative), remain undetermined. The aim of this study was to investigate the prognostic significance and clinicopathological features of HER2-low AGC. Patients and methods: This retrospective analysis involved patients with AGC treated with first-line fluoropyrimidine and platinum-based chemotherapy from 2011 to 2020. Patients were categorized into HER2-zero (HER2 IHC 0), HER2-low (IHC 1+ or 2+/ISH-negative), and HER2-positive (IHC 2+/ISH-positive or 3+) groups. Results: Among 548 patients analyzed, 33.0%, 45.1%, and 21.8% were classified as HER2-zero, HER2-low, and HER2-positive, respectively. The proportions of male patients, intestinal-type histology, esophagogastric junction/cardia involvement, metastatic disease status, ≥2 metastatic sites, liver metastasis, lymph node metastasis, and high serum carcinoembryonic antigen levels were gradually elevated in the HER2-zero, HER2-low, and HER2-positive groups. Overall survival (median) was 13.8, 13.6, and 23.0 months, respectively, with a non-significant trend favoring HER2-positive over HER2-low (adjusted hazard ratio: 0.80; P = .0672). A delayed separation of Kaplan-Meier curves for overall survival between the HER2-zero and HER2-low groups was observed, without reaching statistical significance (adjusted hazard ratio: 1.12; P = .2568). Conclusion: Patients with HER2-low status exhibited intermediate and specific clinicopathological features within the HER2-negative category. In terms of prognosis, HER2-low patients showed a worsening trend compared with HER2-positive patients. This evidence implies that HER2-low status represents a distinct clinical subset, bridging the gap between the HER2-zero and HER2-positive profiles.

8 May 2025 in The Oncologist
Verified
Journal Article
Open access
TSTomoki Sakakida
Tomoki Sakakida
SFShinichiro Fukahori
Shinichiro Fukahori
TMTaro Mizuno
Taro Mizuno
YIYasunobu Ishizuka
Yasunobu Ishizuka
MWMunehiro Wakabayashi
Munehiro Wakabayashi
HTHiroya Taniguchi
Hiroya Taniguchi
Background: Peripheral intravenous 5-fluorouracil (5-FU) administration often causes phlebitis and necessitates catheter replacement, imposing burdens on both patients and healthcare providers. Insertion of a midline catheter (MLC) into the upper arm with tip positioned in the axillary vein may reduce the incidence of phlebitis. This study evaluated the safety and effectiveness of MLC use for continuous 5-FU infusion in cancer patients. Methods: This prospective study included patients with cancer requiring at least 4 days of continuous 5-FU infusion. The primary endpoint was the incidence of phlebitis. Secondary endpoints were the success rate of MLC insertion, complications, and patient-reported outcomes. Results: Of the 61 patients enrolled, 59 were included in the analysis. The median age was 68 years, and primary cancer types were esophageal (51%) and head and neck (46%). The median MLC indwelling duration was 5.5 days (2-28 days). No phlebitis was observed (0%, 95% CI: 0–6.2), achieving the primary endpoint. The insertion success rate was 98.3%, with complications in 6.8%. Over 90% of patients and 80% of healthcare providers reported high satisfaction levels. Conclusion: MLC insertion is a safe and effective approach for continuous 5-FU infusion, eliminating phlebitis, potentially improving patients’ quality of life, and reducing healthcare providers’ workloads. (ClinicalTrials.gov Identifier: jRCTs042230058).

14 October 2026 in Cancer Reports
Verified
Journal Article
Open access
PDF file
TMTaro Mizuno
Taro Mizuno
YNYukiya Narita
Yukiya Narita
TATaiju Ando
Taiju Ando
YIYasunobu Ishizuka
Yasunobu Ishizuka
SUSho Umegaki
Sho Umegaki
KMKei Muro
Kei Muro
Background: Hypoalbuminemia has been recognized as a characteristic adverse event associated with zolbetuximab plus chemotherapy in the treatment of claudin 18.2‐positive advanced gastric cancer. However, its incidence, clinical predictors, and management in real‐world settings remain unclear. Aims: We aimed to characterize the course of hypoalbuminemia during zolbetuximab‐based therapy and identify factors associated with its severity and recovery. Methods and Results: We retrospectively analyzed patients with advanced gastric cancer treated with zolbetuximab plus chemotherapy at a single center, tracking serial serum albumin levels. Severe hypoalbuminemia was defined as a nadir albumin < 2.0 g/dL and/or a ≥ 1.0 g/dL decrease from baseline. Associations between severe hypoalbuminemia and clinicopathological factors were assessed, along with its management strategies. A total of 39 patients were included in the analysis. Hypoalbuminemia occurred in all patients, and 20 (51.3%) developed severe hypoalbuminemia. Prior total gastrectomy was associated with a lower incidence of severe hypoalbuminemia (0% vs. 58.8%, p = 0.02), whereas persistent nausea and/or vomiting beyond the zolbetuximab infusion during the first cycle was associated with a higher risk (63.0% vs. 25.0%, p = 0.04). Recovery of serum albumin levels was observed in 18 patients (46.2%) and occurred more frequently among those who temporarily interrupted zolbetuximab plus chemotherapy or zolbetuximab alone (66.7% vs. 28.6%, p = 0.03). Conclusion: Severe hypoalbuminemia was common in patients receiving zolbetuximab plus chemotherapy in real‐world practice. The absence of prior total gastrectomy and the presence of persistent post‐infusion nausea and/or vomiting may help identify patients at risk. The observed association between temporary treatment interruption and albumin recovery may provide insights into the management of hypoalbuminemia.

12 April 2026 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
KHKazunori Honda
Kazunori Honda
KSKazuhiro Shimomura
Kazuhiro Shimomura
HTHiroya Taniguchi
Hiroya Taniguchi
SKShigenori Kadowaki
Shigenori Kadowaki
TMToshiki Masuishi
Toshiki Masuishi
KMKei Muro
Kei Muro
Background: Financial toxicity is increasingly recognized as a major barrier to high-quality cancer care. However, regimen-specific estimates of out-of-pocket (OOP) costs are rarely available at treatment planning. We developed VEST-Ca (Visualization of Estimated Self-pay Treatment Costs for Cancer), a rule-based visualization tool to estimate OOP expenditures for systemic anticancer therapy under Japan’s universal health coverage system, and evaluated its agreement with claims-derived expenditures. Methods: We conducted a single-center retrospective agreement study including adults with solid tumors who received outpatient systemic therapy for at least 4 months. Actual 4-month OOP expenditures were extracted from claims data. VEST-Ca simulated OOP costs using drug prices, dosing schedules, and patient-specific reimbursement ceilings under the high-cost medical expense benefit system. Accuracy was defined as (simulated OOP/actual OOP) × 100 (%). Agreement was assessed using Bland–Altman analysis. A prespecified sensitivity analysis excluded computed tomography (CT) and medical certificate–related charges. Results: Among 41 enrolled patients, 21 were included after excluding those with indeterminate ceiling categories. Median actual 4-month OOP expenditure was JPY 160 930, compared with a median simulated cost of JPY 121 068. Median accuracy was 93.1% and improved to 100% after excluding CT and certificate-related charges. Bland–Altman analysis showed a small negative bias (−11 705 JPY), which decreased in sensitivity analysis. Conclusions: VEST-Ca demonstrated high claims-based agreement across diverse systemic regimens. A simple rule-based cost estimation tool may facilitate financial counseling and support shared decision-making in oncology.